Omar Chamdine1, Ghada Ahmad Saad Elhawary2, Ahmad Samir Alfaar3, Ibrahim Qaddoumi4. 1. King Fahad Specialist Hospital, Dammam, Saudi Arabia. 2. Ain Shams University Hospitals, Cairo, Egypt. 3. Charite Medical University, Berlin, Germany. 4. Department of Oncology, Saint Jude Children's Research Hospital, 262 Danny Thomas Place, MS 260, Memphis, TN, 38105-3678, USA. ibrahim.qaddoumi@stjude.org.
Abstract
PURPOSE: Incidence of BS primitive neuroectodermal tumors (BS-PNET) in children is not reported to date. Our main objectives were to estimate the incidence and report the outcome of BS-PNET in children. METHODS: Data were collected using the Surveillance Epidemiology and End Results cancer registry. RESULTS: From 1973 to 2013, we identified 83 pediatric patients (aged 0-21 years). Patients were divided into two age groups (0-3 years and 4-21 years). Median overall survival was 53 months. Patients in the older age group had a significant survival advantage (P < 0.001), as did those who received three modalities of therapy (surgery, chemotherapy, and radiation therapy) (P < 0.001) and patients with gross or subtotal tumor resection (P < 0.001). CONCLUSIONS: This study presents the first estimate of incidence and the largest cohort of pediatric BS-PNETs to date. A high index of suspicion of BS-PNET in similar cases is crucial for diagnosis, treatment, and outcome.
PURPOSE: Incidence of BS primitive neuroectodermal tumors (BS-PNET) in children is not reported to date. Our main objectives were to estimate the incidence and report the outcome of BS-PNET in children. METHODS: Data were collected using the Surveillance Epidemiology and End Results cancer registry. RESULTS: From 1973 to 2013, we identified 83 pediatric patients (aged 0-21 years). Patients were divided into two age groups (0-3 years and 4-21 years). Median overall survival was 53 months. Patients in the older age group had a significant survival advantage (P < 0.001), as did those who received three modalities of therapy (surgery, chemotherapy, and radiation therapy) (P < 0.001) and patients with gross or subtotal tumor resection (P < 0.001). CONCLUSIONS: This study presents the first estimate of incidence and the largest cohort of pediatric BS-PNETs to date. A high index of suspicion of BS-PNET in similar cases is crucial for diagnosis, treatment, and outcome.
Authors: L B Rorke; J Q Trojanowski; V M Lee; R A Zimmerman; L N Sutton; J A Biegel; J W Goldwein; R J Packer Journal: Brain Pathol Date: 1997-04 Impact factor: 6.508
Authors: D Zagzag; D C Miller; E Knopp; J P Farmer; M Lee; S Biria; A Pellicer; F J Epstein; J C Allen Journal: Pediatrics Date: 2000-11 Impact factor: 7.124
Authors: Alexandra Sufit; Andrew M Donson; Diane K Birks; Jeffrey A Knipstein; Laura Z Fenton; Paul Jedlicka; Todd C Hankinson; Michael H Handler; Nicholas K Foreman Journal: J Neurosurg Pediatr Date: 2012-06-29 Impact factor: 2.375
Authors: Daniel Picard; Suzanne Miller; Cynthia E Hawkins; Eric Bouffet; Hazel A Rogers; Tiffany S Y Chan; Seung-Ki Kim; Young-Shin Ra; Jason Fangusaro; Andrey Korshunov; Helen Toledano; Hideo Nakamura; James T Hayden; Jennifer Chan; Lucie Lafay-Cousin; Pingzhao Hu; Xing Fan; Karin M Muraszko; Scott L Pomeroy; Ching C Lau; Ho-Keung Ng; Chris Jones; Timothy Van Meter; Steven C Clifford; Charles Eberhart; Amar Gajjar; Stefan M Pfister; Richard G Grundy; Annie Huang Journal: Lancet Oncol Date: 2012-06-11 Impact factor: 41.316